# Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

> **NCT03080883** · PHASE3 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 370 (actual)

## Conditions studied

- Cerebral Vein Thrombosis
- Deep Vein Thrombosis
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Pulmonary Embolism
- Splanchnic Vein Thrombosis

## Interventions

- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT03080883
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-14
- **Primary completion:** 2022-06-07
- **Final completion:** 2025-05-09
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080883, "Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03080883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*